prikaz prve stranice dokumenta Evaluation of the Neutralizing Antibody STE90-C11 against SARS-CoV-2 Delta Infection and Its Recognition of Other Variants of Concerns
  Download
PDF 3.64 MB
Scientific paper - Original scientific paper
Evaluation of the Neutralizing Antibody STE90-C11 against SARS-CoV-2 Delta Infection and Its Recognition of Other Variants of Concerns
Viruses, 15 (2023), 11; 2153. https://doi.org/10.3390/v15112153
Abassi, Leila; Bertoglio, Federico; Mačak Šafranko, Željka; Schirrmann, Thomas; Greweling-Pils, Marina; Seifert, Oliver; Khan, Fawad; Katzmarzyk, Maeva; Jacobsen, Henning; Gödecke, Natascha; Heine, Philip Alexander; Frenzel, André; Nowack, Helena; Dübel, Stefan; Kurolt, Ivan-Christian; Kontermann, Roland E.; Markotić, Alemka; Schubert, Maren; Hust, Michael; Čičin-Šain, Luka More authors...

Cite this document

Abassi, L., Bertoglio, F., Mačak Šafranko, Ž., Schirrmann, T., Greweling Pils, M., Seifert, O. ... Čičin Šain, L. (2023). Evaluation of the Neutralizing Antibody STE90-C11 against SARS-CoV-2 Delta Infection and Its Recognition of Other Variants of Concerns. Viruses, 15. (11). doi: 10.3390/v15112153

Abassi, Leila, et al. "Evaluation of the Neutralizing Antibody STE90-C11 against SARS-CoV-2 Delta Infection and Its Recognition of Other Variants of Concerns." Viruses, vol. 15, no. 11, 2023. https://doi.org/10.3390/v15112153

Abassi, Leila, Federico Bertoglio, Željka Mačak Šafranko, Thomas Schirrmann, Marina Greweling Pils, Oliver Seifert, Fawad Khan, et al. "Evaluation of the Neutralizing Antibody STE90-C11 against SARS-CoV-2 Delta Infection and Its Recognition of Other Variants of Concerns." Viruses 15, no. 11 (2023). https://doi.org/10.3390/v15112153

Abassi, L., et al. (2023) 'Evaluation of the Neutralizing Antibody STE90-C11 against SARS-CoV-2 Delta Infection and Its Recognition of Other Variants of Concerns', Viruses, 15(11). doi: 10.3390/v15112153

Abassi L, Bertoglio F, Mačak Šafranko Ž, Schirrmann T, Greweling Pils M, Seifert O, and sur.. Evaluation of the Neutralizing Antibody STE90-C11 against SARS-CoV-2 Delta Infection and Its Recognition of Other Variants of Concerns. Viruses [Internet]. 2023 October 25 [cited 2024 November 18];15(11). doi: 10.3390/v15112153

L. Abassi, et al., "Evaluation of the Neutralizing Antibody STE90-C11 against SARS-CoV-2 Delta Infection and Its Recognition of Other Variants of Concerns", Viruses, vol. 15, no. 11, October 2023. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:877574. [Accessed: 18 November 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Evaluation of the Neutralizing Antibody STE90-C11 against SARS-CoV-2 Delta Infection and Its Recognition of Other Variants of Concerns
AuthorLeila Abassi
AuthorFederico Bertoglio
AuthorŽeljka Mačak Šafranko
AuthorThomas Schirrmann
AuthorMarina Greweling-Pils
AuthorOliver Seifert
AuthorFawad Khan
AuthorMaeva Katzmarzyk
AuthorHenning Jacobsen
AuthorNatascha Gödecke
AuthorPhilip Alexander Heine
AuthorAndré Frenzel
AuthorHelena Nowack
AuthorStefan Dübel
AuthorIvan-Christian Kurolt
AuthorRoland E. Kontermann
AuthorAlemka Markotić
AuthorMaren Schubert
AuthorMichael Hust
AuthorLuka Čičin-Šain
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Infectious Diseases)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Infectology
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Basic Medical Sciences
Immunology
Abstract (english)
As of now, the COVID-19 pandemic has spread to over 770 million confirmed cases and caused approximately 7 million deaths. While several vaccines and monoclonal antibodies (mAb) have been developed and deployed, natural selection against immune recognition of viral antigens by antibodies has fueled the evolution of new emerging variants and limited the immune protection by vaccines and mAb. To optimize the efficiency of mAb, it is imperative to understand how they neutralize the variants of concern (VoCs) and to investigate the mutations responsible for immune escape. In this study, we show the in vitro neutralizing effects of a previously described monoclonal antibody (STE90-C11) against the SARS-CoV-2 Delta variant (B.1.617.2) and its in vivo effects in therapeutic and prophylactic settings. We also show that the Omicron variant avoids recognition by this mAb. To define which mutations are responsible for the escape in the Omicron variant, we used a library of pseudovirus mutants carrying each of the mutations present in the Omicron VoC individually. We show that either 501Y or 417K point mutations were sufficient for the escape of Omicron recognition by STE90-C11. To test how escape mutations act against a combination of antibodies, we tested the same library against bispecific antibodies, recognizing two discrete regions of the spike antigen. While Omicron escaped the control by the bispecific antibodies, the same antibodies controlled all mutants with individual mutations.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleViruses
Numberingvol. 15, no. 11, 2153
e-ISSN1999-4915
DOIhttps://doi.org/10.3390/v15112153
URN:NBNurn:nbn:hr:184:877574
Publication2023-10-25
Document URLhttps://www.mdpi.com/1999-4915/15/11/2153
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2023-10-26 10:36:55